Credit Suisse Downgrades Thoratec (THOR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Credit Suisse Downgrades Thoratec (THOR) to Neutral
August 11, 2014 7:17 AM EDT
Northland Capital Markets downgraded Thoratec (NASDAQ: THOR) from Outperform to Market Perform with a price target of $26.00 (from $46.00).
Analyst Suraj Kalia said, "THOR Q2 results epitomized poor tactical execution & clinical messaging in the field.... More
August 7, 2014 2:38 PM EDT
BofA/Merrill Lynch downgraded Thoratec (NASDAQ: THOR) from Buy to Neutral with a price target of $25.00 (from $41.00), saying the bad news was widespread in Q2.
Analyst Bob Hopkins noted weak LVAD market growth of only 1%, share losses to HTWR, turnover in... More
August 7, 2014 10:54 AM EDT
BTIG downgraded Thoratec (NASDAQ: THOR) from Buy to Neutral. Analyst Sean Lavin said Thoratec 'dropped a bomb' with its large Q2 miss and reduced guidance.
"We are stunned by THORs results and feel the drastic reduction in guidance point to deeper problems than... More
August 7, 2014 7:08 AM EDT
Goldman Sachs downgraded Thoratec (NASDAQ: THOR) from Buy to Neutral with a price target of $28.00 (from $38.00).
Analyst David H. Roman said, "Given these results and revised forward outlook, we are downgrading shares of Thoratec (THOR) from Buy to Neutral and reduce our... More
August 6, 2014 4:06 PM EDT
Thoratec Corp (NASDAQ: THOR) reported Q2 EPS of $0.43, in-line with the analyst estimate of $0.43. Revenue for the quarter came in at $118.1 million versus the consensus estimate of $128.3 million.
The HeartMate® product line contributed $102.0 million, a decrease of 12 percent while the CentriMag product line contributed $13.1 million, an increase of... More
